Effects of 1,25-dihydroxyvitamin D 3 on experimental periodontitis and AhR/NF-κB/NLRP3 inflammasome pathway in a mouse model Vitamin D has been known to have important regulatory functions in inflammation and immune response and shows inhibitory effects on experimental periodontitis in animal models. However, the potential mechanism has yet to be clarified. Recent studies have highlighted Aryl hydrocarbon receptor (AhR) and its downstream signaling as a crucial regulator of immune homeostasis and inflammatory regulation. Objective:
Introduction
Periodontitis is a bacterium-induced chronic immunoinflammatory disease that leads to loss of gingival tissue and bone support of the dentition. 1 Porphyromonas gingivalis (P. gingivalis) has been reported to be important in periodontitis and it can release virulence factors, such as lipopolysaccharide, inducing host immune response and periodontal tissue damage. 2 After being exposed to lipopolysaccharide from P. gingivalis, gingival epithelial cells produced a variety of inflammatory mediators, including interleukin-1β (IL-1β) and interleukin-6 (IL-6), exerting various immunomodulatory functions in periodontal tissues. 3, 4 Thus, regulating the inflammatory response in gingival epithelia may become a potential strategy for periodontitis treatment.
Recently, vitamin D 3 has emerged as a crucial regulator of the immune system, and it has immunomodulatory properties in different inflammatory diseases, including inflammatory bowel disease and oral lichen planus. 5, 6 Active form of vitamin D 3 , 1,25-dihydroxyvitamin D 3 (VD3), is reported to alleviate excessive inflammatory response in many epithelial cells, including intestinal epithelial cells and keratinocytes. 6, 7 Although in clinical research, the beneficial effect of VD3 on periodontitis still remains to be confirmed; 8, 9 reduced alveolar bone loss has been observed in murine experimental periodontitis after supplementation with the stable form of VD3. 10, 11 These findings suggest that VD3 may have potential protective effect on periodontitis, and this effect might be linked to its immunomodulatory functions on the oral epithelium.
Aryl hydrocarbon receptor (AhR) is a ligandactivated transcription factor, and its immunoregulatory function has been highlighted recently. 12 AhR activation has been shown to improve immune homeostasis in epithelial cells, and stimulation of oral commensal bacteria can enhance its activation in oral epithelial cells. 13, 14 NLR pyrin domain-containing 3 (NLRP3) is a pattern recognition receptor with a key role in host defense against pathogens. 15 NLRP3 assembles a multi-protein complex (inflammasome), which consists of NLRP3, apoptosis-associated speck-like protein (ASC) and caspase-1. 16 Current research on macrophages has shown that the NLRP3 inflammasome has a crosstalk with AhR and nuclear factor-κB (NF-κB), a pivotal regulator of inflammation-related gene transcription. 17, 18 Moreover, the activation of AhR signaling can be increased by VD3 in immune cells, including kidney epithelium-derived cells. 19 USA) under anaerobic conditions. At the age of 7 weeks, the mice in P and V groups were orally inoculated with 100 μl phosphate buffered saline (PBS) containing 2% carboxymethylcellulose and 10 9 colony-forming units of live bacteria, 3 times at 2-day intervals within 5 days. 10, 11 The mice in N group received 100 μl PBS with 2% carboxymethylcellulose. 10, 11 Treatment with VD3
The mice in V group were intraperitoneally injected with VD3 (Sigma-Aldrich Co., St. Louis, MO, USA) every J Appl Oral Sci. 2019;27:e20180713 3/10 other day from 11 wk of age, and they were injected the last time 1 day before sacrifice, at wk 19. VD3 was dissolved in sterile corn oil (VD3 dose: 2.5 μg/kg body weight), and sterile corn oil was used as vehicle (the mice in N and P groups were given only corn oil). All thirty mice were sacrificed by overdose of diethyl ether inhalation at the end of the experiment. 
Quantification of bone loss

Results
VD3 reduces alveolar bone loss in experimental periodontitis
Quantitative analysis of alveolar bone loss revealed that both P. gingivalis-infected groups (V and P groups) had more bone loss than the normal control group. However, V group showed obviously decreased bone loss after VD3 administration for 8 wks when compared to P group (Figure 1 ). This result indicates the attenuated bone loss after VD3 treatment.
VD3 increases VDR expression in gingival epithelia
A s s h o w n by w e s t e r n b l o t a n a l y s e s a n d immunohistochemical staining, VDR protein levels in the gingival epithelium were markedly increased in V group compared with other two groups (N and P groups). Moreover, no significant difference in VDR expression was observed between N and P groups Table 1 ).
VD3 inhibits IL-1β and IL-6 production in gingival epithelia Western blot analyses showed amplified expression of IL-1β and IL-6 in P group compared with N group.
Furthermore, attenuated expression of these cytokines was found in V group compared with P group (Figure 4) .
Similarly, immunohistochemical staining revealed that the expression of both cytokines was greater in mice with periodontitis than in their normal counterparts (P vs. N, and V vs. N), while the expression was reduced Table 1 ).
Discussion
Recently, VD3 has been considered an important regulator of immune response in different inflammatory diseases, such as type 1 diabetes and inflammatory bowel disease. 5, 21 In clinical research, vitamin D supplementation was reported to decrease the periodontitis, for it can produce various inflammationrelated proteins. 26, 27 In this study, we showed amplified VDR expression in gingival epithelia, accompanied with decreased bone loss after VD3 administration, suggesting that the attenuated periodontal damage in periodontitis may be due to the interaction between VDR and other inflammation-related proteins in gingival epithelia. VDR is a key protein in VD3 signaling, and widely exists in epithelial cells, including intestinal and corneal epithelial cells. 28, 29 After binding to VD3, VDR becomes heterodimerized with the retinoid X receptor and regulates the synthesis of inflammatory proteins. 30 In addition, we found that the expression of AhR and its downstream CYP1A1 was upregulated in gingival epithelia in periodontitis mice compared with their normal controls. Upon VD3 treatment, the expression was further enhanced. These data suggest that VD3 may inhibit periodontitis through increasing the AhR signaling activation. AhR is newly reported to improve immune homeostasis in diseases related to excessive proinflammatory status, such as Crohn's disease. 31 Upon binding to its ligand, AhR activates the transcription of target genes including CYP1A1 and other downstream inflammatory proteins. 32 AhR signaling can be activated by some products of bacteria, including lipopolysaccharide in immune cells, and its enhanced activation is found to correlate with the alleviation of inflammatory response. 12, 33 In monocytic cells, VD3 can increase the activation of AhR signaling, possibly through binding to the promoter sequences required for the activation of this signaling. 19 Furthermore, we found that the phosphorylation of NF-κB p65 and the expression of NLRP3, ASC and caspase-1 were increased in the gingival epithelium in periodontitis, while they were decreased upon VD3 treatment. These observations indicate that the periodontitis attenuation by VD3 may involve the repression of NF-κB and NLRP3 inflammasome activation by AhR signaling. NF-κB is crucial in the major signaling networks for inflammatory response modulation. 34 As an important member of NF-κB family, NF-κB p65 can be significantly activated by lipopolysaccharide, the major virulence factor of P. gingivalis, and its phosphorylation was greatly associated with periodontal damage. 35 Upon stimulation by lipopolysaccharide, NF-κB becomes phosphorylated, and binds to the NF-κB binding sites in the NLRP3 promoter region, resulting in the NLRP3 inflammasome activation in immune cells. 36 In macrophages, the activation of AhR signaling blocks NF-κB binding sites and masks NF-κB transcription activity, subsequently suppressing NLRP3 inflammasome activation. 17 In our experiments, the IL-1β and IL-6 expression in gingival epithelia was elevated in all periodontitis mice compared with their normal controls. Moreover, reduced expression of these cytokines occurred upon VD3 injection. These findings implicate that the alleviation of experimental periodontitis by VD3 may be partly due to the inhibition of IL-1β and IL-6 production, which may result from the change in AhR/NF-κB/NLRP3 inflammasome pathway. Previous research has shown the important role of IL-1β in the host defense against bacterial infections and the pathogenesis of periodontitis. 37 It can strongly promote the IL-6 production, a potent stimulator of alveolar bone resorption in this periodontal disease. 38 IL-6 upregulates the expression of RANKL (osteoclast differentiation factor), and promotes osteoclastogenesis. 39 Lipopolysaccharide can trigger the phosphorylation of NF-κB, and subsequently leads to the activation of NLRP3 inflammasome pathway, which processes pro-IL-1β into its mature form IL-1β. 17, 40 In immune cells such as macrophages, through the interaction with NF-κB, activated AhR signaling can inhibit NLRP3 inflammasome formation and subsequent secretion of IL-1β, and other proinflammatory cytokines, improves inflammatory response. 17 In clinical research, the VD3 effect on periodontal disease still remains controversial. Several studies on adults showed that lower serum 25-hydroxyvitamin D 3 levels were significantly associated with periodontitis. 41, 42 However, some investigators demonstrated that serum vitamin D levels or vitamin D supplementation did not seem to be related to periodontal status. 8, 43 These different findings may partly be attributed to wrong study designs, short follow-up duration or cross- Thus, in the study on periodontitis, especially on its inflammatory regulation, we should consider the genetic differences between different animal species, and between experimental animals and humans.
This study showed the VD3 effect on experimental periodontitis in a mouse model, but there were some limitations. First, the mouse strain we used was more susceptible to human oral bacterium P. gingivalis and tended to exhibit severe periodontitis, compared with some other mouse strains and animal species. Second, we did not compare the in vivo VD3 concentrations before and after VD3 treatment to show the its supplementation levels. Third, we did not examine some inflammatory markers closely related to periodontitis, such as periodontal inflammatory infiltrate in mice. To further elucidate the precise effect and mechanisms of VD3 on periodontitis, in future experiments we can choose different animals to induce periodontitis, such as different mouse strains with AhR knockdown or rat ligature models, to mimic the complex human host response to microbial challenge and treatment.
Moreover, we can detect more parameters, as periodontal VD3 concentrations and inflammatory infiltrate in periodontal tissues, to confirm the VD3 status and periodontal inflammation.
Conclusions
We observed that VD3 attenuated P. gingivalis- 
